Update on the umbrella clinical trial of the PIONeeR project as of February 28, 2023
Date : 28 February 2023
Category : News,Pioneer Project
Enrollment in the biomarker study is now completed (see news from January 5, 2023) but remains open in the PIONeeR Project’s umbrella clinical trial, which is evaluating the benefits of multiple treatment combinations in patients with different immune profiles, again with the unique goal of identifying the combination that has the best chance of improving patient survival and quality of life.
As of February 28, 2023, 126 patients have been screened for and 87 have entered the PIONeeR umbrella clinical trial (72,5% of expected inclusions).
NB: It is currently possible to directly include patients eligible for PIONeeR TRIAL after the same progression times as those previously included in PIONeeR BIOMARKERS:
- From 6 weeks of treatment for 2nd and 3rd lines
- After 12 weeks of treatment for 1st lines
PIONeeR TRIAL
Centre | Nombre de patients screenés Number of patients screened | Nombre de patients inclus Number of patients included |
CEPCM Marseille | 84 | 57 |
Oncopole Toulouse | 17 | 13 |
CLC Léon Bérard, Lyon | 25 | 17 |
Total | 126 | 87 |
Back